29 related articles for article (PubMed ID: 38471994)
1. Dabrafenib for Pilocytic Astrocytoma With
Tanaka R; Mrachek K; Arocho-Quinones E; Carlberg VM; Smith C; Kurzrock R; Deshmukh T
JCO Precis Oncol; 2024 May; 8():e2400055. PubMed ID: 38781546
[TBL] [Abstract][Full Text] [Related]
2. Dabrafenib Effective in Pediatric Glioma.
Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
[TBL] [Abstract][Full Text] [Related]
3. Dabrafenib plus trametinib in patients with BRAF
Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib and trametinib in BRAFV600E mutated glioma.
Brown NF; Carter T; Kitchen N; Mulholland P
CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy Win in BRAF-Mutant Gliomas.
Cancer Discov; 2023 Nov; 13(11):2299-2300. PubMed ID: 37732735
[TBL] [Abstract][Full Text] [Related]
6. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
[TBL] [Abstract][Full Text] [Related]
7. [Dabrafénib and tramétinib in BRAF V600E mutated pediatric gliomas].
Giorgis O; Doz F
Bull Cancer; 2024 May; 111(5):429-430. PubMed ID: 38471994
[No Abstract] [Full Text] [Related]
8. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
Khunger A; Khunger M; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
[TBL] [Abstract][Full Text] [Related]
9. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
Jiang L; Yang P; Liu Y; Li J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
Gibney GT; Zager JS
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
12. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]